Repaglinide 0.5 mg Tablets (Repaglinide)

Adult dose

1. Monotherapy The recommended initial dose is 0.5 mg of repaglinide per dose. Determine the dose through titration at intervals of 1 or 2 weeks. Patients taking another oral hypoglycemic agent may switch directly to this drug; the recommended initial dose in this case is 1 mg per dose. The recommended maximum dose is 4 mg per administration. Administer 2, 3, or 4 times daily before meals, according to the patient's meal schedule. The total daily dose must not exceed 16 mg. Use extra caution when administering and titrating the dose in debilitated or malnourished patients. Although this drug is excreted mainly in the bile, caution should also be exercised in patients with renal impairment. 2. Combination therapy If blood glucose is not adequately controlled with monotherapy, this drug may be used in combination with metformin or a thiazolidinedione. The initial dose and dose adjustment are the same as for monotherapy. Adjust the dose of each agent very carefully to the minimum required to achieve the desired pharmacologic effect. If this adjustment is not made appropriately, the incidence of hypoglycemic symptoms may increase. Adequate monitoring of fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) is required to prevent overdose or an increased possibility of secondary treatment failure.

This medication lowers blood glucose levels and can cause a dangerous condition known as hypoglycemia. Special caution is needed when used in conjunction with other hypoglycemic agents or metformin as the risk of hypoglycemia may increase. If blood glucose control is inadequate, a switch to insulin therapy may be necessary. The risk of hypoglycemia increases during stress from fever, infection, surgery, and adjustments to medications may be required. This drug should not be used in certain patients, such as those with allergies to this medication or its components, type 1 diabetes patients, women who are pregnant or breastfeeding, children under 18 years old, and patients with severe liver or kidney dysfunction. Additionally, it should not be combined with medications such as gemfibrozil. Patients with impaired liver or kidney function, heart disease, or poor nutritional status, as well as elderly patients, should use this medication cautiously. Side effects like hypoglycemia, visual disturbances, gastrointestinal disorders, abnormal liver function, allergic reactions, and others may occur while taking this medication. Hypoglycemia is primarily influenced by individual lifestyle habits such as meals, exercise, and stress, and in severe cases, immediate treatment may be required. Also, this drug may interact with other medications, especially specific antibiotics, antifungals, anticoagulants, beta-blockers, and alcohol, so caution is advised when taken with these substances. Pregnant or breastfeeding women should not take this medication, and safety in children under 18 has not been established. Elderly patients should regularly monitor their blood glucose levels and take this medication cautiously due to diminished bodily functions. In the event of overdose, hypoglycemic symptoms may appear, and immediate carbohydrate intake or hospital treatment may be necessary in severe cases. Lastly, this medication should be stored out of reach of children and kept in its original container for safety.

• Hypoglycemia
• visual impairment
• abdominal pain
• diarrhea
• nausea
• vomiting
• constipation
• increased liver enzymes
• severe liver dysfunction
• erythema

This medication should be stored in a sealed container to protect it from air and moisture. It is recommended to store the medication at room temperature between 15 to 25 degrees Celsius in a dry place with low humidity. This will help maintain the efficacy of the medication over time.

Appearance

Convex white circular tablet

Package unit

100 tablets/bottle, 30 tablets/bottle